he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源IP
- 2022-04-262013年国际抗癫痫联会抗癫痫药使用指南
- 2022-04-25癫痫孕妇使用抗癫痫药物会增加流产后果吗?
- 2022-04-12十个女人,八个贫血,五种常见的便宜货,让你充满气血
- 2022-04-05FDA批准Aptiom用于治疗患者癫痫发作
- 2021-12-20常见的癫痫病病因有哪些您真的
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 十个女人,八个贫血,五种常见的便宜货,让你充满气血
- 综述:癫痫持续状态诊治最新进展
- 2013国际抗癫痫联合会抗癫痫药用指南
- 癫痫患者手术评估新型工具
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- FDA批准Aptiom用于治疗患者癫痫发作
- 小便疼痛
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 癫痫症状 如何护理癫痫患者?
- 治疗细菌性炎 6食谱防治效果好(2)
- 抗癫痫药物预防新发癫痫:任重而道远
- 广西百色破获药案:涉及74家药店,3000多盒
- Cell Death Dis:SPATS2调节细胞周期,促进肝癌的发生和发展
- 慢性炎症状 关注男性健康
- 胀痛怎么办?试试这五种缓解方法
- JAMA:阳性结果的文章一定更受关注吗?
- 月经性癫痫患者妊娠期癫痫控制更好
- 继发性痛经和原发性痛经有什么区别?
- 男性乳腺增生 为什么男性乳腺增生?
- 癫痫患者在治疗时应注意什么?
- 暖宝宝可以治疗痛经吗 如何缓解痛经呢(2)
- 如何治疗精囊炎症状?
- 2015 神经系统疾病诊疗进展
- JPD:左旋多巴-治疗帕金森病的卡比多巴肠凝胶与生活质量和症状有什么关系?
- 白癜风的遗传是什么?
- Cell重磅:解决了近百年的问题!研究发现了闪过记忆的潜在机制
- 奥硝唑、甲硝唑和替硝唑有什么区别?
- 癫痫病用什么外科手术
- 癫痫病吃什蜂蜜好处多
- 泡温泉时不应相反的事情
- 癫痫病婴儿的病因与治疗
- 癫痫的治疗新方法 中医拔罐治癫痫小新方法(2)
- 癫痫病的早期症状 患有癫痫万不可吃饭它(2)
- 癫痫病从新治疗方法
- 癫痫病人的饮食和孤独有哪些需要注意的
- 洋甘菊奎宁的沐浴法 洋甘菊奎宁能预防感冒
- 癫痫病的病变有哪些呢
- 倾角多少算正常 如何维持正常倾角不变
- 癫痫病手术治疗法医院